Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from MRNA

A whale with a lot of money to spend has taken a noticeably bearish stance on Moderna. Looking at options history for Moderna (NASDAQ:MRNA) we detected 18 strange trades.

Benzinga

Technical Levels For Salesforce Investors To Watch After Earnings

Saleforce.com Inc. (NASDAQ: MRNA) shares are trading higher Wednesday after the company reported better-than-expected fourth-quarter financial results and issued guidance above estimates.

Benzinga

Expert Ratings For Moderna

Within the last quarter, Moderna (NASDAQ:MRNA) has observed the following analyst ratings:

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

3 Worst Performing Stocks in the S&P 500 Year-to-Date

S&P 500 stocks have been plummeting amid concerns about tighter monetary policy and the escalating war between Russia and Ukraine. This has triggered further selloffs, causing renowned stocks PayPal (PYPL), Moderna (MRNA), and EPAM Systems (EPAM) to lose momentum lately. Let’s discuss.

StockNews.com

Arbutus Hits Moderna With New Suit Claiming COVID-19 Vaccine Patent(s)

Arbutus Biopharma Corporation (NASDAQ: ABUS) and Genevant have sued Moderna Inc (NASDAQ: MRNA) for

Benzinga

Check Out What Whales Are Doing With MRNA

Someone with a lot of money to spend has taken a bullish stance on Moderna (NASDAQ:MRNA). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Longer Waiting Period Between mRNA COVID-19 Doses May Cut Heart Inflammation Risk, CDC Suggests

The Centers for Disease Control and Prevention said that younger males should consider waiting longer between doses of Pfizer Inc's (NYSE: PFE) / BioNTech SE (NASDAQ: BNTX) and Moderna

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Will Moderna Be 'One Of The Most Valuable Healthcare Companies' In The World? Steve Weiss Believes So

Moderna Inc (NASDAQ: MRNA) is on the move Thursday following strong quarterly financial results. Short Hills Capital's Steve Weiss decided to pick up additional shares of the commercial-stage biotech company after the report.

Benzinga

Moderna Rallies After Earnings Print: Could A Technical Reversal Be In Sight?

Moderna Inc. (NASDAQ: MRNA) shares are trading after the company reported better-than-expected fourth-quarter EPS and sales results and announced a new $3 billion buyback.

Benzinga

What's Going On With Moderna Shares Today?

Moderna Inc (NASDAQ: MRNA) shares are trading higher by 9.7% at $149.11 after the company reported better-than-expected fourth-quarter EPS and sales results and announced a new $3 billion buyback.

Benzinga

Moderna Beats On Q4 Earnings, Announces $3B Buyback; Expects ~$19B In FY22 COVID-19 Vax Sales

Moderna Inc (NASDAQ:MRNA) reports a Q4 EPS of $11.29, a turnaround from an EPS loss of $(0.69) a year ago, beating the consensus estimate of $9.90. The Company clocked Q4 revenues of $7.21 billion compared to just $571 million a year ago, beating the consensus of $6.79 billion. Product sales were $6.9…

Benzinga

5 Stocks Trending on Reddit That are Worth Buying

The retail trading boom led stocks like Gamestop (GME) to skyrocket last year, but the gains did not last. However, popular stocks on Reddit like Microsoft (MSFT), Moderna (MRNA), ON Semiconductor (ON), Chemours (CC), and MSC Industrial (MSM) could be poised for a run given their sound fundamentals and solid…

StockNews.com

Moderna, Thermo Fisher Join Forces To Manufacture COVID-19 Vaccine, Other Drugs

Moderna Inc (NASDAQ: MRNA) has en

Benzinga

Check Out What Whales Are Doing With MRNA

A whale with a lot of money to spend has taken a noticeably bullish stance on Moderna. Looking at options history for Moderna (NASDAQ:MRNA) we detected 18 strange trades.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Moderna Adds Three New mRNA-Based Development Programs To Its Pipeline

Moderna Inc (NASDAQ: MRNA) said it is deve

Benzinga

Moderna Says COVID-19 Booster To Be Ready By August, But Dicey If Omicron-Specific Needed: Reuters

Moderna Inc's (NASDAQ: MRNA) CEO, Stephane Bancel, told Reuters that an

Benzinga

Moderna-Rovi Seal 10-Year Deal Extension To Make mRNA Drugs

Spain's Laboratorios Farmaceuticos Rovi SA has agreed on a 10-year extension

Benzinga

Moderna CEO Sells Shares, Deletes Social Media: What You Need To Know

Moderna Inc (NASDAQ: MRNA) shares are down more than 40% since the start of the year and continue to trend lower Monday.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Menstrual Irregularities Cases After mRNA COVID-19 Vaccine - EMA Reviews Cases

The European Medicines Agency's safety committee is reviewing reports of heavy menstrual bleeding and absence of menstruation af

Benzinga

Moderna Whale Trades For February 02

A whale with a lot of money to spend has taken a noticeably bullish stance on Moderna. Looking at options history for Moderna (NASDAQ:MRNA) we detected 10 strange trades.

Benzinga

Why Moderna Shares Are Rising Today

Moderna Inc (NASDAQ: MRNA) is trading higher Monday after the U.S. Food and Drug Administration approved the Biologics License Application for SPIKEVAX to prevent COVID-19 in individuals 18 years of age and older.

Benzinga

Moderna Whale Trades Spotted

A whale with a lot of money to spend has taken a noticeably bearish stance on Moderna. Looking at options history for Moderna (NASDAQ:MRNA) we detected 18 strange trades.

Benzinga

IAVI, Moderna Kickstart HIV Vaccine Antigens Trial Delivered Through mRNA Technology

IAVI, the nonprofit scientific research organization, and Moderna Inc (NASDAQ: MRNA) have

Benzinga

After Pfizer, Moderna Kickstarts Omicron-Targeted COVID-19 Vaccine Trial

Moderna Inc (NASDAQ: MRNA) has started a mid-stage study, testing a booster dose of its COVID-19 vaccine specifically

StockNews.com

Down Close to 40% Year-To-Date, Now is a Good Time to Scoop Up Moderna and BioNTech

The ongoing market correction has caused the shares of popular vaccine makers Moderna (MRNA) and BioNTech (BNTX) to decline nearly 40% in price so far this year. However, because the demand for COVID-19 vaccines remains strong globally, these companies are expected to generate substantial revenues and profits in the coming…

1 … 6 7 8 9

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Centers for Disease Control and Prevention

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.